비임상

HOME > 연구실적 > 비임상 > 논문
 
작성일 : 18-05-28 11:19
논문번호 89
논문제목(영문) Bilirubin coating attenuates the inflammatory response to everolimus-coated stents.
국내외구분 국외 SCI여부 SCI(E)
연구책임자역할 교신저자
주저자명 Bae IH
교신저자명 Jeong MH
공동저자명 Bae IH, Park DS, Lee SY, Jang EJ, Shim JW, Lim KS, Park JK, Kim JH, Sim DS, Jeong MH
게제년월일 2018-05-01
ISSN 1552-4973
Impact Factor 3.189
학술지명 Journal of biomedical materials research. Part B, Applied biomaterials
서지사항 0집 / 106권 / 4호,   페이지(1486 - 1495)
요약초록문
(Abstract) 입력		 The aim of this study was to evaluate the effects of bilirubin- and/or everolimus (EVL)-coated stents to prevent arterial neointimal hyperplasia and inflammation in vitro and in vivo. The stents were prepared by spray coating bare metal stents (BMS) with bilirubin and/or EVL. Study groups were divided into (1) BMS, (2) bilirubin-coated stents (BES), (3) commercialized stents (Synergy™; EES), and (4) bilirubin/EVL-coated stents (B-EES). The coating thickness and drug release rates were comparable to previous reports (i.e., <4 µm thickness and 50% drug release in 7 days). Smooth muscle cell migration was inhibited in both EVL-containing groups (20.5 ± 3.80% in EES and 18.4 ± 2.55% in B-EES) compared to the non-EVL-containing groups (78.0 ± 6.41% in BMS and 76.1 ± 4.88% in BES) (n = 10, p < 0.05). Stents were randomly implanted to 40 coronary arteries in 20 pigs and subjected to various analyses after 4 weeks of implantation. As results, the inflammation score was dramatically increased in the EES group (2.1 ± 0.42) compared to that of the other groups (1.5 ± 0.55, 1.3 ± 0.23, and 1.5 ± 0.27 for BMS, BES, and B-EES, respectively, n = 10, p < 0.05). Immunofluorescence analysis revealed that inflammation was prevented in the bilirubin-containing groups (BES and B-EES). However, the percent area of restenosis was decreased in the EVL-containing groups (20.5 ± 4.11% for EES and 18.4 ± 3.61% for B-EES) compared to the non-EVL-containing groups (32.3 ± 6.41% for BMS and 29.6 ± 5.95% for BES, n = 10, p < 0.05). The percent areas of restenosis determined by histopathology, optical coherence tomography, and micro-computed tomography were consistent. In addition, the stent was barely covered in the EES and B-EES groups at 4 weeks postimplantation. These dual drug-coated stents may be especially beneficial to patients who have an increased risk of inflammation. These stents have great potential for use in cardiovascular applications.
파일  89-Bilirubin coating attenuates the inflammatory response to everolimus-coated stents..pdf (1.0M) DATE : 2018-05-28 11:19:40